Seliciclib (Roscovitine) is an Orally Active and Selective CDKs Inhibitor
Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose activity depends on a regulatory subunit-a cyclin. Based on the sequence of the kinase domain, CDKs belong to the CMGC group of kinases, along with MAPKs, Gsk3β, DYRK family and CDK-like kinases. There are around 20 Cyclin-dependent kinases (CDK1-20) known till date....
Flavopiridol (Alvocidib) is a pan CDK Inhibitor
The cyclin-dependent kinases (CDKs) are serine/threonine protein kinases. And it exhibits drives force behind the cell cycle and cell proliferation. CDKs contain at least a catalytic subunit (CDK) and a regulatory subunit (cyclin). To date, at least 10 CDKs and 15 cyclins have been identified. Once activation, CDKs phosphorylate...
NU6102 is a Potent CDK1 and CDK2 Inhibitor
CDKs remain attractive targets for anti-proliferative cancer chemotherapy. they play a central role in cell division and growth. Amongst the cell cycle CDKs, CDK2 has attracted the most attention and its exploitation as a drug target based on structure-based drug design. In this article, we will introduce a potent...
OTS964 is an Orally Active TOPK and CDK11 Inhibitor
TOPK (T–lymphokine-activated killer cell–originated protein kinase, also known as PBK or PDZ-binding kinase) is a Ser/Thr protein kinase. Many types of human cancer, including breast and lung cancers, highly expresses it. Thus, TOPK might be a promising molecular target for drug development. Moreover, TOPK is in the “consensus stemness...